ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: TH-OR18

Tenapanor Controls Serum Phosphorus and Reduces PTH and FGF-23 in Patients on Dialysis with Severe Secondary Hyperparathyroidism

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Weiner, Daniel E., Dialysis Clinic Inc, Boston, Massachusetts, United States
  • Spiegel, David M., Ardelyx Inc, Fremont, California, United States
  • Yang, Yang, Ardelyx Inc, Fremont, California, United States
  • Rosenbaum, David P., Ardelyx Inc, Fremont, California, United States

Secondary hyperparathyroidism (sHPT) is common in patients with chronic kidney failure, and most nephrologists treat parathyroid hormone (PTH) values >600 pg/mL. Hyperphosphatemia may directly contribute to sHPT, making the glands less responsive to therapy. Tenapanor is a first-in-class phosphate absorption inhibitor (PAI) that targets the paracellular pathway, the primary pathway of phosphate absorption.


The phase 3 PHREEDOM trial evaluated the safety and efficacy of tenapanor in patients on dialysis with hyperphosphatemia. Following washout from binders, patients whose serum phosphorus (sP) increased by 1.5 to ≥6.0 mg/dL were randomized. Those randomized to the tenapanor arm received tenapanor 30 mg PO BID for 26 weeks. Serum calcium (sCa), sP, PTH, and FGF23 were measured per protocol. This post-hoc analysis evaluates changes in PTH, FGF23, sP, and sCa among tenapanor-treated patients with baseline PTH >600 pg/mL and at least one post-baseline PTH measure (n=73).


For the 73 participants with severe sHPT (defined as >600 pg/mL), the median baseline PTH was 766 pg/mL with a median absolute (percent) reduction of 280 pg/mL (34.0%) at week 26. Of these 73 patients, 31 had a recorded change in PTH-modifying medication during the treatment period, whereas 42 did not have any recorded change. Among those with medication changes, median PTH reduction was 231 pg/mL (26.9%); among those without changes, PTH reduction was 300 pg/mL (35.4%). Median baseline FGF23 was 15,275 ng/L with a median reduction of 3165 ng/L (40.7%) at the end of the treatment period. The magnitude of the median reductions was similar in the medication change and non-change subgroups (4278 ng/L [40.9%] and 2730 ng/L [38.7%], respectively). On average, sP decreased by 1.8 mg/dL (from 8.0±1.5 mg/dL at baseline), with similar changes in medication change and non-change subgroups (1.9 mg/dL and 1.8 mg/dL, respectively). sCa remained unchanged overall (0.2 mg/dL) and in the medication change and non-change subgroups (0 mg/dL and 0.3 mg/dL, respectively).


Tenapanor effectively lowers sP in patients on maintenance dialysis with severe sHPT and demonstrates that effective sP control with tenapanor improves both PTH and FGF23 concentrations.


  • Commercial Support – Ardelyx, Inc.